Itraconazole Accord Healthcare

Itraconazole, the active ingredient in Itraconazole Accord Healthcare, is an azole antifungal presented as an oral formulation for oral use. It treats systemic and superficial fungal infections in adult patients, including blastomycosis, histoplasmosis, aspergillosis, candidiasis and dermatophytosis.

GNH USA supplies Itraconazole Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Itraconazole is used to treat fungal infections affecting various organ systems.

Blastomycosis: eradicates the organism and resolves pulmonary and disseminated disease Histoplasmosis: clears infection in acute and chronic forms Aspergillosis: treats invasive disease and allergic bronchopulmonary forms Candidiasis: eliminates systemic and mucosal Candida infections Dermatophytosis: resolves skin and nail fungal infections

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Headache - Abdominal pain or dyspepsia - Rash or pruritus - Altered taste sensation

Serious or Rare Side Effects: - Hepatotoxicity, including hepatitis and liver failure - Congestive heart failure or worsening of existing heart failure - Severe allergic reactions such as Stevens‑Johnson syndrome - QT interval prolongation and cardiac arrhythmias

Before prescribing itraconazole, clinicians should consider several safety precautions.

Liver monitoring: assess hepatic function before and during therapy Cardiac assessment: avoid in patients with existing heart failure Drug interaction review: evaluate concomitant medications that affect CYP3A4 Pregnancy and lactation: use only if benefits outweigh potential risks Renal impairment: adjust dosing in severe renal dysfunction Store at room temperature: keep in original container, protect from moisture

Itraconazole has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Rifampin: markedly reduces itraconazole plasma concentrations - Ketoconazole: additive hepatotoxicity when combined - Macrolide antibiotics (e.g., erythromycin, clarithromycin): increase itraconazole levels and risk of toxicity - St. John's wort: induces metabolism leading to loss of efficacy

Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect, requiring INR monitoring - Phenytoin: may lower itraconazole concentrations, reducing effectiveness - Cimetidine: may raise itraconazole levels, necessitating clinical observation